Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing.

Department of Surgery, University of Pennsylvania Medical Center, Philadelphia, PA 19104-4283, USA.
Journal of Vascular Surgery (Impact Factor: 2.98). 07/2007; 45 Suppl A:A39-47. DOI: 10.1016/j.jvs.2007.02.068
Source: PubMed

ABSTRACT During embryonic development, the vasculature is among the first organs to form and is in charge of maintaining metabolic homeostasis by supplying oxygen and nutrients and removing waste products. As one would expect, blood vessels are critical not only for organ growth in the embryo but also for repair of wounded tissue in the adult. An imbalance in angiogenesis (a time-honored term that globally refers to the growth of new blood vessels) contributes to the pathogenesis of numerous malignant, inflammatory, ischemic, infectious, immune, and wound-healing disorders. This review focuses on the central role of the growth of new blood vessels in ischemic and diabetic wound healing and defines the most current nomenclature that describes the neovascularization process in wounds. There are now two well-defined, distinct, yet interrelated processes for the formation of postnatal new blood vessels, angiogenesis, and vasculogenesis. Reviewed are recent new data on vasculogenesis that promise to advance the field of wound healing.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Love "The cost of Traumatic Brain Injuries (TBI) is approximately $56 billion, and more than 5 million Americans alive today have had TBI related injury resulting in a permanent need for help in performing daily activities. Survivors of TBI are often left with significant cognitive, behavioral, and communicative disabilities, and some patients develop long-term medical complications, such as epilepsy." (National Institutes of Neurological Disorders and Stroke, NIH, 2010) INTRODUCTION Traumatic Brain Injuries (TBI) are becoming one of the leading causes of death and life-long disabilities in infants, adolescents, adults and senior citizens (1) . Consequently, there is an increasing concern among parents and health care providers regarding the prevalence of brain injuries in commonly practiced sports; car related accidents, worker injuries as well as increasing number of brain-injured soldiers returning from war theaters. Approximately 1.7 million Americans will experience a brain injury annually, with ~80% of those patients diagnosed with mild-to-moderate TBI (1) . Limited medical and technological tools to address this urgent concern have created a strong need to develop new approaches to treat TBI sufferers. Hyperbaric Oxygen Therapy (HBOT) has been used for more than a 100 years to increase oxygen intake in damaged or oxygen-starved tissues. By increasing atmospheric pressure around the damaged tissue and applying 100% oxygen, the total amount of oxygen in the blood and organs increases, ensuring that all cells are supplied with this life sustaining gas. Evidence of the benefits of HBOT in the treatment of Traumatic Brain Injury has been accumulating for the last 30 years with encouraging results. Recent clinical reports and animal studies support the idea that patients with mild-to-moderate brain injury can greatly accelerate their recovery and reverse damage with HBOT. Currently medications focus on controlling brain injury symptoms rather than brain recovery. HBOT has shown positive benefits for mild-to-moderate TBI now and can reverse damage that is untreatable with drugs.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow-derived endothelial progenitor cells (EPCs) infiltrate into sites of neovascularization in adult tissues and mature into functional blood endothelial cells (BECs) during a process called vasculogenesis. Human marrow-derived EPCs have recently been reported to display a mixed myeloid and lymphatic endothelial cell (LEC) phenotype during inflammation-induced angiogenesis; however, their role in cancer remains poorly understood. We report the in vitro differentiation of human cord blood CD133(+)CD34(+) progenitors into podoplanin(+) cells expressing both myeloid markers (CD11b, CD14) and the canonical LEC markers vascular endothelium growth factor receptor 3 (VEGFR-3), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and prospero homeobox 1 (PROX-1). These podoplanin(+) cells displayed sprouting behavior comparable to that of LECs in vitro and a dual hemangiogenic and lymphangiogenic activity in vivo in an endothelial cell sprouting assay and corneal vascularization assay, respectively. Furthermore, these cells expressed vascular endothelium growth factor (VEGF) family members A, -C, and -D. Thus, bone-marrow derived EPCs stimulate hemangiogenesis and lymphangiogenesis through their ability to differentiate into LECs and to produce angiogenic factors. Importantly, plasma from patients with breast cancer induced differentiation of CD34(+) cord blood progenitors into hemangiogenic and lymphangiogenic CD11b(+) myeloid cells, whereas plasma from healthy women did not have this effect. Consistent with these findings, circulating CD11b(+) cells from breast cancer patients, but not from healthy women, displayed a similar dual angiogenic activity. Taken together, our results show that marrow-derived EPCs become hemangiogenic and lymphangiogenic upon exposure to cancer plasma. These newly identified functions of bone-marrow derived EPCs are expected to influence the diagnosis and treatment of breast cancer.
    OncoImmunology 06/2014; 3:e29080. · 6.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Love "Each year in the United States, there are more than 700,000 [cases of people suffering] strokes. Stroke is the third leading cause of death in the country. And stroke causes more serious long-term disabilities than any other disease. Nearly three-quarters of all strokes occur in people over the age of 65 and the risk of having a stroke more than doubles each decade after the age of 55." (National Institutes of Neurological Disorders and Stroke, NIH, Centers for Disease Control and Prevention, 2004) INTRODUCTION In the U.S. it is estimated that 6.4 million adults have suffered a stroke and another 13 million may have experienced a "silent stroke", loss of brain cells without visible symptoms. The financial burdens associated with stroke treatment and recovery (both direct and indirect) is estimated to be $73 billion dollars for 2010. In spite of modest declining rates of strokes for the last 7 years, the prevalence of this disease continues to constitute a major source of long-term disabilities for the American public, as well as an expanding cost in health care and household budgets. Drug treatments for brain strokes are only available for patients diagnosed 1-3 hours after the onset of a clot induced stroke. With more than 90% of stroke patients falling outside of this treatment group, new treatments must be developed. Therapies that focus on salvaging and protection of brain tissue in this large group of stroke sufferers is a major focus for the medical and scientific community. One treatment that has the proven ability to salvage oxygen starved tissue is hyperbaric oxygen therapy (HBOT). HBOT has been used for more than a 100 years to increase oxygen intake in damaged or oxygen-starved tissues. By increasing atmospheric pressure around the damaged tissue and applying 100% oxygen, the total amount of oxygen in the blood and organs increases, ensuring that all cells are supplied with this life sustaining gas. Evidence of the benefits of HBOT in the treatment of stroke has been accumulating this past decade. With the improvement of imaging technology and better clinical assessment a positive effect of HBOT for stroke patients has been established. Clinical studies and reports in animal models of stroke clearly show a protective effect, as well as a strong therapeutic potential for alleviating neurological symptoms and restoring functionality, even in patients that have suffered a stroke weeks or months earlier.


Available from